水杨酸甲酯钠盐 | 7631-93-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 水杨酸甲酯钠盐
• CAS: 7631-93-8
• 化学式: C8H8NaO3
• 分子量: 175.14
• InChiKey: CJCPHVRHJKYIJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Heteropolysaccharide; process and microorganism for producing it
  申请人：UNILEVER PLC

  公开号：EP0023397A1

  公开（公告）日：1981-02-04

  Biopolymer PS-87, a heteropolysaccharide comprising glucose, galactose, mannose, glucuronic acid and fucose, is pseudoplastic and has a consistency at 20°C of at least 150 poise and a yield stress value at 20°C of at least 30 dynes/cm2. Biopolymer PS-87 is synthesized by a specific strain or mutant of Bacillus polymyxa (NCIB 11429) or by micro-organisms which have undergone genetic manipulations. This heteropolysaccharide has many domestic and industrial applications as a suspending agent or thickener.

  生物聚合物 PS-87 是一种由葡萄糖、半乳糖、甘露糖、葡萄糖醛酸和岩藻糖组成的杂多糖，具有假塑性，在 20°C 时的稠度至少为 150 poise，在 20°C 时的屈服应力值至少为 30 dynes/cm2。生物聚合物 PS-87 是由多粘芽孢杆菌（NCIB 11429）的特定菌株或突变体或经过遗传操作的微生物合成的。这种杂多糖可作为悬浮剂或增稠剂在家庭和工业中广泛应用。
• Use of a thromboxane receptor antagonist to complement arterial surgery
  申请人：GLAXO GROUP LIMITED

  公开号：EP0342030A2

  公开（公告）日：1989-11-15

  The use is described of [1R-[1α(Z),2β,3β,5α]]-(+)-7-[5-[[(1,1′-­biphenyl)-4-yl]methoxy]-3-hydroxy-2-(1-piperidinyl)cyclopentyl]-4-­heptenoic acid or a physiologically acceptable salt, solvate or cyclodextrin complex thereof in the manufacture of medicaments to compliment the surgical removal of an obstruction in an intact artery.

  描述了[1R-[1α(Z),2β,3β,5α]]-(+)-7-[5-[[(1,1′-联苯)-4-基]甲氧基]-3-羟基-2-(1-哌啶基)环戊基]-4-庚烯酸或其生理学上可接受的盐、溶液或环糊精络合物在制造药物中的用途，以补充手术切除完整动脉中的阻塞。
• Use of thromboxane receptor antagonist in pregnancy-induced hypertension and related conditions
  申请人：GLAXO GROUP LIMITED

  公开号：EP0348149A2

  公开（公告）日：1989-12-27

  The use is described of [1R-[1α(Z),2β,3β,5α]]-(+)-7-[5-[[1,1′-­biphenyl)-4-yl]methoxy]-3-hydroxy-2(1-piperidinyl)cyclopentyl]-4-­heptenoic acid or a physiologically acceptable salt, solvate or cyclodextrin complex thereof in the manufacture of medicaments for the therapy or prophylaxis of conditions associated with vasoconstriction and/or platelet aggregation in the uteroplacental circulation and/or excessive synthesis of thromboxane A₂ in a pregnant female subject.

  描述了[1R-[1α(Z),2β,3β,5α]]-(+)-7-[5-[[1,1′-联苯)-4-基]甲氧基]-3-羟基-2(1-哌啶基)环戊基]-4-庚烯酸或其生理上可接受的盐的用途、其溶解物或环糊精络合物，用于制造治疗或预防与怀孕女性子宫胎盘循环中血管收缩和/或血小板聚集和/或血栓素 A₂ 过度合成有关的疾病的药物。
• Pharmaceutical combinations containing a piperidinylcyclopentylheptenoic acid derivative
  申请人：GLAXO GROUP LIMITED

  公开号：EP0332346A2

  公开（公告）日：1989-09-13

  The use is described of both (i) [1R-[1α(Z),2β,3β,5α]]-(+)-7-[5-­[[1,1′-biphenyl)-4-yl]methoxy]-3-hydroxy-2-(1-piperidinyl) cyclopentyl]-4-heptenoic acid or a physiologically acceptable salt, solvate or cyclodextrin complex thereof and (ii) a thrombolytic agent in the therapy or prophylaxis of thrombotic disorders. Pharmaceutical compositions containing both (i) and (ii) are also described.

  描述了(i)[1R-[1α(Z),2β,3β,5α]]-(+)-7-[5-[[1,1′-联苯)-4-基]甲氧基]-3-羟基-2-(1-哌啶基)环戊基]-4-庚烯酸或其生理上可接受的盐的用途、(ii) 用于治疗或预防血栓性疾病的溶栓剂。 还描述了同时含有(i)和(ii)的药物组合物。
• Use of TP-receptor antagonists to modify the action of myofibroblasts
  申请人：GLAXO GROUP LIMITED

  公开号：EP0337739A2

  公开（公告）日：1989-10-18

  The use is described of TP-receptor antagonists in the manufacture of medicaments for the treatment or prophylaxis of conditions caused or exacerbated by myofibroblast cell contraction.

  描述了 TP 受体拮抗剂在制造治疗或预防由肌成纤维细胞收缩引起或加剧的疾病的药物中的用途。